Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-10)

In this article, we will discuss Olaparib (Description-10). So, let’s get strarted.

Drug Interactions
Based on the data from a drug-interaction trial (n=57), the AUC and Cmax of olaparib increased by 170% and 42%, respectively, when Olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) may increase the AUC and Cmax of olaparib by 121% and 14%, respectively.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.